{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:18Z","timestamp":1753892118992,"version":"3.41.2"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T00:00:00Z","timestamp":1628553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>The compound [3-(1H-benzimidazol-2-methylene)-5-(2-methylphenylaminosulfo)-2-indolone], known as Indo5, is a novel selective inhibitor of c-Met and Trks, and it is a promising anticancer candidate against hepatocellular carcinoma (HCC). Assessing the pharmacokinetic properties, tissue distribution, and toxicity of Indo5 is critical for its medicinal evaluation. A series of sensitive and specific liquid chromatography-tandem mass spectrometry methods were developed and validated to determine the concentration of Indo5 in rat plasma and tissue homogenates. These methods were then applied to investigate the pharmacokinetics and tissue distribution of Indo5 in rats. After intravenous injection of Indo5, the maximum concentration (C<jats:sub>max<\/jats:sub>) and the time at which C<jats:sub>max<\/jats:sub> was reached (T<jats:sub>max<\/jats:sub>) were 1,565.3 \u00b1 286.2\u00a0ng\/ml and 1\u00a0min, respectively. After oral administration, C<jats:sub>max<\/jats:sub> and T<jats:sub>max<\/jats:sub> were 54.7 \u00b1 10.4\u00a0ng\/ml and 2.0 \u00b1 0.48\u00a0h, respectively. We calculated the absolute oral bioavailability of Indo5 in rats to be 1.59%. Following intravenous injection, the concentrations of Indo5 in various tissues showed the following order: liver &amp;gt; kidney \u2248 heart &amp;gt; lung \u2248 large intestine \u2248 small intestine \u2248 stomach &amp;gt; spleen &amp;gt; brain \u2248 testes; hence, Indo5 distributed highest in the liver and could not cross the blood\u2013brain or blood\u2013testes barriers. Continuous injection of Indo5 for 21\u00a0days did not lead to liver injury, considering unchanged ALT and AST levels, normal histological architecture of the liver, and normal number and frequencies of immune cells in the liver, indicating a very low toxicity of Indo5 <jats:italic>in vivo<\/jats:italic>. Collectively, our findings provide a comprehensive understanding of the biological actions of Indo5 <jats:italic>in vivo and further support<\/jats:italic> its development as an antitumor treatment for HCC patients.<\/jats:p>","DOI":"10.3389\/fphar.2021.711126","type":"journal-article","created":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T07:59:57Z","timestamp":1628582397000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Pharmacokinetics, Tissue Distribution, and Primary Safety Evaluation of Indo5, a Novel Selective Inhibitor of c-Met and Trks"],"prefix":"10.3389","volume":"12","author":[{"given":"Teng","family":"Luo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Xiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ying","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Guo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gui-Fang","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Qun","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1002\/ptr.6171","article-title":"Milk Thistle (Silybum marianum): A Concise Overview on its Chemistry, Pharmacological, and Nutraceutical Uses in Liver Diseases","volume":"32","author":"Abenavoli","year":"2018","journal-title":"Phytotherapy Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3390\/medicina55090526","article-title":"Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies","volume":"55","author":"Alqahtani","year":"2019","journal-title":"Medicina"},{"key":"B3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1080\/17474124.2019.1549989","article-title":"Trends in Hepatocellular Carcinoma Due to Non-Alcoholic Fatty Liver Disease","volume":"13","author":"Bertot","year":"2019","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.3390\/molecules22111942","article-title":"Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism","volume":"22","author":"Bijak","year":"2017","journal-title":"Molecules"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1002\/jps.21111","article-title":"Development of Nonsurfactant Cyclodextrin Nanoparticles Loaded with Anticancer Drug Paclitaxel","volume":"97","author":"Bilensoy","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/ijn.s52634","article-title":"Nanotechnology-Based Drug Delivery Systems and Herbal Medicines: A Review","volume":"9","author":"Bonif\u00e1cio","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/s0140-6736(16)32453-9","article-title":"Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1016\/j.ejca.2013.05.028","article-title":"Regorafenib as Second-Line Therapy for Intermediate or Advanced Hepatocellular Carcinoma: Multicentre, Open-Label, Phase II Safety Study","volume":"49","author":"Bruix","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"442","DOI":"10.5246\/jcps.2011.05.055","article-title":"Advances in the Nanoparticle Drug Delivery Systems of Silymarin","volume":"20","author":"Chen","year":"2011","journal-title":"J. Chin. Pharm. Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s1470-2045(08)70285-7","article-title":"Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejps.2012.05.015","article-title":"Enhanced Oral Bioavailability of Paclitaxel in Pluronic\/LHR Mixed Polymeric Micelles: Preparation, In Vitro and In Vivo Evaluation","volume":"47","author":"Dahmani","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nrd4539","article-title":"Organs-On-Chips at the Frontiers of Drug Discovery","volume":"14","author":"Esch","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1200\/jco.2011.39.9394","article-title":"Efficacy and Safety of Regorafenib in Patients with Metastatic And\/or Unresectable GI Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial","volume":"30","author":"George","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0140-6736(12)61900-x","article-title":"Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): an International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3109\/07357909509031919","article-title":"Taxanes: a New Class of Antitumor Agents","volume":"13","author":"Huizing","year":"1995","journal-title":"Cancer Invest."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3109\/10717544.2015.1124473","article-title":"Optimized Permeation Enhancer for Topical Delivery of 5-Fluorouracil-Loaded Elastic Liposome Using Design Expert: Part II","volume":"23","author":"Hussain","year":"2016","journal-title":"Drug Deliv."},{"key":"B17","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.eujim.2011.05.002","article-title":"Reassessing Bioavailability of Silymarin","volume":"16","author":"Javed","year":"2011","journal-title":"Altern. Med. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/bcpt.12365","article-title":"The Adverse Effects of Sorafenib in Patients with Advanced Cancers","volume":"116","author":"Li","year":"","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ijpharm.2015.05.070","article-title":"Preparation and Characterization of Paclitaxel Nanosuspension Using Novel Emulsification Method by Combining High Speed Homogenizer and High Pressure Homogenization","volume":"490","author":"Li","year":"","journal-title":"Int. J. Pharmaceutics"},{"key":"B20","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1200\/jco.1997.15.1.110","article-title":"Patient Preferences for Oral versus Intravenous Palliative Chemotherapy","volume":"15","author":"Liu","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13046-019-1104-4","article-title":"A Selective C-Met and Trks Inhibitor Indo5 Suppresses Hepatocellular Carcinoma Growth","volume":"38","author":"Luo","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40005-017-0372-2","article-title":"Polymeric Nanomedicines for Poorly Soluble Drugs in Oral Delivery Systems: An Update","volume":"48","author":"Ma","year":"2018","journal-title":"J. Pharm. Invest."},{"key":"B24","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s10637-010-9421-7","article-title":"Paclitaxel in Self-Micro Emulsifying Formulations: Oral Bioavailability Study in Mice","volume":"29","author":"Oostendorp","year":"2011","journal-title":"Invest. New Drugs"},{"key":"B25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2174\/187152011796011073","article-title":"Molecular Mechanisms of Liver Cancer","volume":"11","author":"Pan","year":"2011","journal-title":"Anticancer Agents Med. Chem."},{"key":"B26","first-page":"S7","article-title":"Clinical Pharmacology and Metabolism of Taxol (Paclitaxel): Update 1993","volume":"5","author":"Rowinsky","year":"1994","journal-title":"Ann. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/s0928-0987(00)00153-6","article-title":"Modulation of Oral Bioavailability of Anticancer Drugs: from Mouse to Man","volume":"12","author":"Schellens","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000343850","article-title":"Clinical Trials in Hepatocellular Carcinoma: An Update","volume":"2","author":"Shen","year":"2013","journal-title":"Liver Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1053\/j.gastro.2016.11.048","article-title":"Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis","volume":"152","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"volume-title":"World Cancer Report","year":"2014","author":"Stewart","key":"B30"},{"key":"B31","first-page":"5737","article-title":"Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future","volume":"35","author":"Stotz","year":"2015","journal-title":"Anticancer Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1021\/jm980123i","article-title":"Synthesis and Biological Evaluations of 3-Substituted Indolin-2-Ones: a Novel Class of Tyrosine Kinase Inhibitors that Exhibit Selectivity toward Particular Receptor Tyrosine Kinases","volume":"41","author":"Sun","year":"1998","journal-title":"J. Med. Chem."},{"key":"B33","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.3390\/molecules19055538","article-title":"Pharmacokinetics, Tissue Distribution, Excretion and Plasma Protein Binding Studies of Wogonin in Rats","volume":"19","author":"Talbi","year":"2014","journal-title":"Molecules"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1021\/acs.molpharmaceut.7b00278","article-title":"Efficient Codelivery of Paclitaxel and Curcumin by Novel Bottlebrush Copolymer-Based Micelles","volume":"14","author":"Yao","year":"2017","journal-title":"Mol. Pharmaceutics"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.711126\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T08:00:08Z","timestamp":1628582408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.711126\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,10]]},"references-count":34,"alternative-id":["10.3389\/fphar.2021.711126"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.711126","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2021,8,10]]},"article-number":"711126"}}